<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-09-09">9 September 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Pierre</forename><surname>Delanaye</surname></persName>
							<email>pierre_delanaye@yahoo.fr</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Nephrology, Dialysis and Transplantation</orgName>
								<orgName type="institution">University of Liège Hospital (ULg CHU)</orgName>
								<address>
									<postCode>4000</postCode>
									<settlement>Liège, Belgium</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Toralf</forename><surname>Melsom</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Section of Nephrology</orgName>
								<orgName type="laboratory">Metabolic and Renal Research Group</orgName>
								<orgName type="institution">UiT The Arctic University of Norway</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">University Hospital of North Norway</orgName>
								<address>
									<settlement>Tromsø, Norway</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Natalie</forename><surname>Ebert</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute of Public Health</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sten-Erik</forename><surname>Bäck</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Clinical Chemistry</orgName>
								<orgName type="institution">Skåne University Hospital</orgName>
								<address>
									<settlement>Lund</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christophe</forename><surname>Mariat</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Nephrology</orgName>
								<orgName type="department" key="dep2">Dialysis, Transplantation and Hypertension</orgName>
								<orgName type="institution" key="instit1">CHU Hôpital Nord</orgName>
								<orgName type="institution" key="instit2">University Jean Monnet</orgName>
								<address>
									<country>PRES</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">Université de LYON</orgName>
								<address>
									<settlement>Saint-Etienne</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Etienne</forename><surname>Cavalier</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Clinical Chemistry</orgName>
								<orgName type="institution">University of Liège Hospital (ULg CHU)</orgName>
								<address>
									<settlement>Liège</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jonas</forename><surname>Björk</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Occupational and Environmental Medicine</orgName>
								<orgName type="institution">Lund University</orgName>
								<address>
									<settlement>Lund</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anders</forename><surname>Christensson</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Nephrology</orgName>
								<orgName type="institution">Skåne University Hospital</orgName>
								<address>
									<settlement>Lund</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulf</forename><surname>Nyman</surname></persName>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Department of Translational Medicine</orgName>
								<orgName type="department" key="dep2">Division of Medical Radiology</orgName>
								<orgName type="institution">Skåne University Hospital</orgName>
								<address>
									<settlement>Malmö</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Esteban</forename><surname>Porrini</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">University of La Laguna</orgName>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">CIBICAN-ITB</orgName>
								<orgName type="institution" key="instit2">Hospital Universtario de Canarias</orgName>
								<address>
									<settlement>Tenerife</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Giuseppe</forename><surname>Remuzzi</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Centro di Ricerche Cliniche per le Malattie Rare &apos;Aldo e Cele Daccò&apos;</orgName>
								<orgName type="department" key="dep2">Istituto di Ricerche Farmacologiche Mario Negri</orgName>
								<orgName type="institution">Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso</orgName>
								<address>
									<settlement>Bergamo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Unit of Nephrology</orgName>
								<orgName type="institution">Azienda Socio Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII</orgName>
								<address>
									<settlement>Bergamo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Piero</forename><surname>Ruggenenti</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Centro di Ricerche Cliniche per le Malattie Rare &apos;Aldo e Cele Daccò&apos;</orgName>
								<orgName type="department" key="dep2">Istituto di Ricerche Farmacologiche Mario Negri</orgName>
								<orgName type="institution">Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso</orgName>
								<address>
									<settlement>Bergamo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Unit of Nephrology</orgName>
								<orgName type="institution">Azienda Socio Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII</orgName>
								<address>
									<settlement>Bergamo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elke</forename><surname>Schaeffner</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute of Public Health</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Inga</forename><surname>Soveri</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Medical Sciences</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<settlement>Uppsala</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gunnar</forename><surname>Sterner</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Nephrology</orgName>
								<orgName type="institution">Skåne University Hospital</orgName>
								<address>
									<settlement>Malmö</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bjørn</forename><forename type="middle">Odvar</forename><surname>Eriksen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Section of Nephrology</orgName>
								<orgName type="laboratory">Metabolic and Renal Research Group</orgName>
								<orgName type="institution">UiT The Arctic University of Norway</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">University Hospital of North Norway</orgName>
								<address>
									<settlement>Tromsø, Norway</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Flavio</forename><surname>Gaspari</surname></persName>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">IRCCS -Istituto di Ricerche Farmacologiche &apos;Mario Negri&apos;</orgName>
								<orgName type="department" key="dep2">Centro di Ricerche Cliniche per le Malattie Rare &apos;Aldo e Cele Daccò&apos;</orgName>
								<address>
									<settlement>Ranica, Bergamo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-09-09">9 September 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">71362E4859E9C68B131A80A79F2429E3</idno>
					<idno type="DOI">10.1093/ckj/sfw071</idno>
					<note type="submission">Received: May 18, 2016. Accepted: July 11, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:10+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>glomerular filtration rate, iohexol</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>A reliable assessment of glomerular filtration rate (GFR) is of paramount importance in clinical practice as well as epidemiological and clinical research settings.</s><s>It is recommended by Kidney Disease: Improving Global Outcomes guidelines in specific populations (anorectic, cirrhotic, obese, renal and non-renal transplant patients) where estimation equations are unreliable.</s><s>Measured GFR is the only valuable test to confirm or confute the status of chronic kidney disease (CKD), to evaluate the slope of renal function decay over time, to assess the suitability of living kidney donors and for dosing of potentially toxic medication with a narrow therapeutic index.</s><s>Abnormally elevated GFR or hyperfiltration in patients with diabetes or obesity can be correctly diagnosed only by measuring GFR.</s><s>GFR measurement contributes to assessing the true CKD prevalence rate, avoiding discrepancies due to GFR estimation with different equations.</s><s>Using measured GFR, successfully accomplished in large epidemiological studies, is the only way to study the potential link between decreased renal function and cardiovascular or total mortality, being sure that this association is not due to confounders, i.e. non-GFR determinants of biomarkers.</s><s>In clinical research, it has been shown that measured GFR (or measured GFR slope) as a secondary endpoint as compared with estimated GFR detected subtle treatment effects and obtained these results with a comparatively smaller sample size than trials choosing estimated GFR. Measuring GFR by iohexol has several advantages: simplicity, low cost, stability and low interlaboratory variation.</s><s>Iohexol plasma clearance represents the best chance for implementing a standardized GFR measurement protocol applicable worldwide both in clinical practice and in research.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>The first part of this review article focused on practical and technical aspects of iohexol plasma clearance [i.e.</s><s>plasma iohexol analysis and clearance investigation procedures (number of samples and timing)].</s><s>In this second part, we focus on the indication of glomerular filtration rate (GFR) measurements in clinical practice as wellas in epidemiological and clinical research.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Role of iohexol in clinical practice</head><p><s>It is beyond the scope of this article to review and summarize all clinical settings where measured GFR is recommended <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>.</s><s>Briefly, and as stated in the Kidney Disease: Improving Global Outcomes guidelines <ref type="bibr" target="#b3">[4]</ref>, additional tests for GFR assessment are needed in specific populations where creatinine-based equations are unreliable, because serum creatinine is largely dependent on muscle mass <ref type="bibr" target="#b4">[5]</ref>.</s><s>Cystatin C can be used as an alternative test but is influenced by other non-GFR-related factors such as obesity, thyroid function and cardiovascular risk factors <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>. Thus, measured GFR is recommended for specific patients or subjects with an abnormal muscule mass or body composition, such as anorectic, cirrhotic, obese and renal and non-renal transplant patients <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>.</s><s>If, in daily practice, repeated measurements of GFR in these patient groups are infeasible, at least one GFR measurement will indicate the relationship between serum creatinine (or plasma cystatin C) concentrations and the 'true' GFR level.</s><s>Measured GFR is the only available test to certify GFR levels, and according to the GFR level, to confirm or refute chronic kidney disease (CKD) status.</s><s>Also, in longitudinal studies, several authors have described the limitations of estimated GFR (eGFR) to adequately assess the true decline in measured GFR <ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref>.</s></p><p><s>Another clear indication for GFR measurement applies when an exact value of GFR is required <ref type="bibr" target="#b3">[4]</ref>.</s><s>The two typical examples are the measurement of GFR before potential living kidney donation or before prescribing a potentially toxic hydrosoluble drug with a narrow therapeutic window, e.g.</s><s>aminoglycosides or cisplatin <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref>.</s><s>Finally, without measured GFR, one pathological condition in nephrology would remain undetected.</s><s>Abnormally elevated GFR, or hyperfiltration, has been established as an initial pathophysiological step to CKD in patients with diabetes and may also be of importance in common conditions such as obesity, metabolic syndrome and prediabetes <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>Importantly, data suggest that treating hyperfiltration with angiotensinconverting enzyme inhibitors could be beneficial <ref type="bibr" target="#b26">[27,</ref><ref type="bibr" target="#b27">28]</ref>.</s><s>However, it is well accepted that the condition of hyperfiltration can only be correctly detected with measured GFR, as all eGFR equations perform poorly in this specific, highly relevant pathological state <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b21">22]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Role of iohexol in clinical research</head><p><s>The role of measured GFR in both clinical epidemiology and clinical research is another important objective of this review.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical epidemiology</head><p><s>Measuring GFR is also feasible in large epidemiological studies.</s><s>For example, the CRIC (Chronic Renal Insufficiency Cohort), BIS (Berlin Initiative Study), AGES-II (Age, Gene/Environment Susceptibility) and RENIS (Renal Iohexol Clearance Survey) studies are four large observational cohorts with GFR measured by iothalamate (CRIC) and iohexol (BIS, AGES-II and RENIS) <ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref>.</s><s>The RENIS study is interesting since it is a European observational study with a representative sample of the general population in Tromsø, Norway, and GFR measurement has been repeated in the follow-up <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b30">31]</ref>.</s><s>The BIS study also measured GFR with iohexol plasma clearance in a large population-based cohort of older patients (mean age 79 years), which also proves the feasibility of performing measured GFR in this fragile age group <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b33">34]</ref>.</s></p><p><s>Data from numerous epidemiological studies show high but different prevalence rates of CKD in the general population.</s><s>Moreover, CKD status is associated with mortality, especially cardiovascular mortality <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref>.</s><s>However, the vast majority of these epidemiological studies are based on eGFR.</s><s>It is known that all eGFR equations, based on creatinine and/or cystatin C, have limitations, particularly at high GFR levels <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40]</ref>.</s><s>Also, it has been shown that the prevalence of CKD is largely dependent on the equation [Modification of Diet in Renal Disease (MDRD) versus Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) versus Cockcroft-Gault] and biomarker used (creatinine versus cystatin C) <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b40">41]</ref>.</s><s>The major limitations of GFR estimations include issues in calibration of the biomarkers <ref type="bibr" target="#b41">[42]</ref>, different performance of the estimators according to age <ref type="bibr" target="#b42">[43]</ref> and lack of precision in high GFR values <ref type="bibr" target="#b1">[2]</ref>.</s><s>Even if data are limited, we cannot exclude that the prevalence of CKD in the general population, defined as GFR &lt;60 mL/min/1.73</s><s>m 2 , may be much lower with measured GFR compared with eGFR <ref type="bibr" target="#b30">[31]</ref>.</s></p><p><s>The higher risk of mortality associated with decreased GFR is another hot topic in clinical epidemiology <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b43">44]</ref>.</s><s>Once again, associations between cardiovascular risk and CKD have been described with eGFR in the vast majority of patients.</s><s>This fact could lead to confusion or false-positive associations, as eGFR may include variables such as gender, ethnicity, weight and age that are per se risk factors for cardiovascular morbidity and mortality and often referred to as 'non-GFR determinant'.</s><s>The different weights of these factors in different equations might explain differences in the magnitude of association between cardiovascular outcomes and eGFR <ref type="bibr" target="#b44">[45,</ref><ref type="bibr" target="#b46">46]</ref>.</s><s>Some authors have suggested a closer association between mortality and the Cockcroft-Gault equation compared with the MDRD study equation <ref type="bibr" target="#b44">[45]</ref>.</s><s>The fact that age is handled differently mathematically in the two equations could explain the discrepancies.</s><s>The association between eGFR and mortality also varies with the biomarker considered.</s><s>For cystatin C-versus creatinine-based equations, an increased hazard ratio for all-cause mortality was found for eGFR &lt;85 mL/min/1.73</s><s>m 2 based on cystatin C, but when the eGFR was based on creatinine, the hazard ratio increased when eGFR was &lt;60 mL/min/1.73</s><s>m 2 <ref type="bibr" target="#b47">[47,</ref><ref type="bibr" target="#b48">48]</ref>.</s></p><p><s>Also, the classical association between the MDRD (or CKD-EPI) equation and mortality is U-shaped, with a higher mortality at high GFR values.</s><s>This U-shaped association has not been found when cystatin C-based equations were investigated <ref type="bibr" target="#b35">[36,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b49">49]</ref>.</s><s>Overall, it is virtually impossible to know whether this U-shaped association is (i) a mathematical artefact, (ii) due to hyperfiltration (true elevated GFR) or (iii) due to sarcopenia and falsely low creatinine concentrations.</s><s>Measured GFR has recently been discredited because it was insufficiently able to predict mortality compared with creatinine-or cystatin C-based equations <ref type="bibr" target="#b50">[50]</ref>.</s><s>Using measured GFR is, however, the only way to really study the potential link between decreased renal function and cardiovascular or total mortality, being sure that this association is not due to confounders, i.e. non-GFR determinants of biomarkers [muscule mass (serum creatinine), traditional cardiovascular risk factors (cystatin C) and non-traditional cardiovascular risk factors (creatinine and cystatin C)] <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b51">[51]</ref><ref type="bibr" target="#b52">[52]</ref><ref type="bibr" target="#b53">[53]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical research</head><p><s>In nephrological trials, the classic clinical endpoints are mortality, end-stage renal disease or doubling of serum creatinine.</s><s>However, these are relatively rare events developing over a long period of time, especially in low-risk patients.</s><s>For this reason, clinical studies in nephrology require large sample sizes and a long follow-up time.</s><s>Therefore, several authors proposed socalled surrogate markers instead of 'true' endpoints.</s><s>GFR and albuminuria are the two most reliable surrogate markers to use <ref type="bibr" target="#b54">[54]</ref>.</s><s>However, eGFR lacks precision, especially at high GFR levels, and is, as mentioned above, not only dependent on GFR, but also on non-GFR determinants included in the equations.</s><s>Moreover, several authors have described large discrepancies between slopes based on measured GFR versus eGFR <ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref>.</s><s>The majority of these studies have shown that the decline in measured GFR is underestimated by eGFR.</s><s>For these reasons, detection of potential differences in GFR slopes between two groups (e.g. one treated with active therapy and the other with placebo) requires larger sample sizes with eGFR than with measured GFR.</s><s>An example is the trial of belatacept in renal transplant patients, which showed a benefit of belatacept therapy when measured GFR was used, whereas a non-significant difference was observed with eGFR <ref type="bibr" target="#b55">[55]</ref>.</s><s>Importantly, the number of patients with measured GFR in the three groups was relatively small (n = 32 in the intensive belatacept group, n = 37 in the less intensive group and n = 27 in the cyclosporine group).</s><s>Another illustrative example is the ALADIN (A Long-Acting Somatostatin on Disease Progression in Nephropathy due to Autosomal Dominant Polycystic Kidney Disease) trial in which the efficacy of somatostatin in polycystic kidney disease was studied.</s><s>The slope of measured GFR was an important secondary endpoint.</s><s>The authors were able to show that the slope of measured GFR was significantly different between treatment groups (n = 36 and 34 in the active and placebo arm, respectively) <ref type="bibr" target="#b56">[56]</ref>.</s><s>Such important results would have been missed if only eGFR had been used <ref type="bibr" target="#b20">[21]</ref>.</s><s>A similar trial with similar results was published using tolvaptan.</s><s>The authors also showed a significantly different slope in eGFR after 3 years of follow-up between the tolvaptan and placebo groups, but had to include 1445 patients to detect this significant difference <ref type="bibr" target="#b57">[57]</ref>.</s></p><p><s>The lack of precision of eGFR is also particularly important in the context of drug dosage adaptation.</s><s>It is beyond the scope of this article to discuss all the limitations of equations in this context <ref type="bibr" target="#b58">[58]</ref>.</s><s>Due to these limitations, the European Medicines Agency now recommends that 'a method accurately measuring GFR using an exogenous marker [should be] used in pharmacokinetic studies in subjects with decreased renal function' <ref type="bibr" target="#b59">[59]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>In conclusion, both in clinical practice and in research, measured GFR is considered too rarely.</s><s>Nephrology is certainly the only discipline where a gold standard measurement is so uncommonly used.</s><s>Measuring GFR by iohexol has several advantages: simplicity, low cost, stability and low interlaboratory variation.</s><s>We are convinced that iohexol plasma clearance is the best chance to implement a standardized GFR measurement protocol that would be applicable worldwide both in clinical practice and in research.</s><s>Even if it is not as perfect as the 'gold standard' method (inulin urinary clearance), iohexol plasma clearance appears to provide the best compromise between physiology, reliability and feasibility.</s></p></div>		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest statement</head><p><s>None declared.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Measured GFR as a confirmatory test for estimated GFR</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="2305" to="2313" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The applicability of eGFR equations to different populations</title>
		<author>
			<persName><forename type="first">P</forename><surname>Delanaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mariat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Nephrol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="513" to="522" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Measurement of glomerular filtration rate</title>
		<author>
			<persName><forename type="first">F</forename><surname>Gaspari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Perico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Remuzzi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int Suppl</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="S151" to="S154" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease</title>
	</analytic>
	<monogr>
		<title level="j">Kidney Int Suppl</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1" to="150" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Serum creatinine as an index of renal function: new insights into old concepts</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Perrone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Madias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1933" to="1953" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Residual associations of inflammatory markers with eGFR after accounting for measured GFR in a community-based cohort without CKD</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vtn</forename><surname>Stefansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">D</forename><surname>Mathisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="2802" to="2886" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Knight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Verhave</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Spiegelman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1416" to="1421" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Prevalence of chronic kidney disease in the United States</title>
		<author>
			<persName><forename type="first">J</forename><surname>Coresh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Selvin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Stevens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">298</biblScope>
			<biblScope unit="page" from="2038" to="2047" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Factors other than glomerular filtration rate affect serum cystatin C levels</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Greene</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="652" to="660" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Potential contribution of adipose tissue to elevated serum cystatin C in human obesity</title>
		<author>
			<persName><forename type="first">N</forename><surname>Naour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fellahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Renucci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Obesity (Silver Spring)</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="2121" to="2126" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Impact of thyroid dysfunction on serum cystatin C</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fricker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wiesli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brandle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1944" to="1947" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa</title>
		<author>
			<persName><forename type="first">P</forename><surname>Delanaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cavalier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Radermecker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephron Clin Pract</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="158" to="163" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Estimated glomerular filtration rate in renal transplantation: the nephrologist in the mist</title>
		<author>
			<persName><forename type="first">S</forename><surname>Luis-Lima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marrero-Miranda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>González-Rinne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="2625" to="2633" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">MDRD versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients</title>
		<author>
			<persName><forename type="first">I</forename><surname>Masson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Flamant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Maillard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="1211" to="1217" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">GFR estimating equations and liver disease</title>
		<author>
			<persName><forename type="first">T</forename><surname>Beben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Rifkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Chronic Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="337" to="342" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Modification of Diet in Renal Disease versus Chronic Kidney Disease Epidemiology Collaboration equation to estimate glomerular filtration rate in obese patients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bouquegneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vidal-Petiot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vrtovsnik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="122" to="130" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The GFR and GFR decline cannot be accurately estimated in type 2 diabetics</title>
		<author>
			<persName><forename type="first">F</forename><surname>Gaspari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ruggenenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Porrini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="164" to="173" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Rule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Chapman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="854" to="862" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Rate of kidney function decline and risk of hospitalizations in stage 3A CKD</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1946" to="1955" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Slezak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Rule</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="880" to="887" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ruggenenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gaspari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cannata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e32533</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Creatininebased equations for the adjustment of drug dosage in an obese population</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bouquegneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vidal-Petiot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Moranne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="349" to="361" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Pai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Nafziger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Bertino</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="4006" to="4011" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Dooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Poole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rischin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="44" to="51" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Glomerular hemodynamics in severe obesity</title>
		<author>
			<persName><forename type="first">A</forename><surname>Chagnac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Weinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korzets</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Renal Physiol</title>
		<imprint>
			<biblScope unit="volume">278</biblScope>
			<biblScope unit="page" from="F817" to="F822" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Prediabetes and risk of glomerular hyperfiltration and albuminuria in the general nondiabetic population: a prospective cohort study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Melsom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vtn</forename><surname>Stefansson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="841" to="850" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Glomerular hyperfiltration and renal disease progression in type 2 diabetes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ruggenenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Porrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gaspari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="2061" to="2068" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The hyperfiltration theory: a paradigm shift in nephrology</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Brenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">V</forename><surname>Lawler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Mackenzie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1774" to="1777" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Chronic Renal Insufficiency Cohort Study (CRIC): overview and summary of selected findings</title>
		<author>
			<persName><forename type="first">M</forename><surname>Denker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Boyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="2073" to="2083" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">GFR normalized to total body water allows comparisons across genders and body sizes</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">O</forename><surname>Eriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Melsom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">D</forename><surname>Mathisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1517" to="1525" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Cystatin C is not a better estimator of GFR than plasma creatinine in the general population</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">O</forename><surname>Eriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">D</forename><surname>Mathisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Melsom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="1305" to="1311" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Two novel equations to estimate kidney function in persons aged 70 years or older</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Schaeffner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delanaye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="471" to="481" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Midlife blood pressure and late-life GFR and albuminuria: an elderly general population cohort</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Inker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Okparavero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tighiouart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="240" to="248" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The Berlin initiative study: the methodology of exploring kidney function in the elderly by combining a longitudinal and cross-sectional approach</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Schaeffner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Der Giet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gaedeke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="203" to="210" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Relationship between chronic kidney disease prevalence and end-stage renal disease risk</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Hallan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Vikse</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Nephrol Hypertens</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="286" to="291" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Matsushita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Der Velde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Astor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="2073" to="2081" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review</title>
		<author>
			<persName><forename type="first">K</forename><surname>Brück</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Jager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dounousi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="6" to="16" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">CKD prevalence varies across the European general population</title>
		<author>
			<persName><forename type="first">K</forename><surname>Brück</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Stel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gambaro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2135" to="2147" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Predictors of declining glomerular filtration rate in a population-based chronic kidney disease cohort</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">O</forename><surname>Eriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tomtum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">C</forename><surname>Ingebretsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephron Clin Pract</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="41" to="50" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">A new equation to estimate glomerular filtration rate</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Schmid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="604" to="612" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Creatinine-or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease</title>
		<author>
			<persName><forename type="first">P</forename><surname>Delanaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cavalier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Moranne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Nephrol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">57</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration</title>
		<author>
			<persName><forename type="first">J</forename><surname>Coresh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Eknoyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2811" to="2812" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">A new estimating glomerular filtration rate equation for the full age spectrum</title>
		<author>
			<persName><forename type="first">H</forename><surname>Pottel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hoste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dubourg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="798" to="806" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Age and association of kidney measures with mortality and end-stage renal disease</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Hallan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Matsushita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">308</biblScope>
			<biblScope unit="page">2349</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">Prevalence and prognostic impact of chronic kidney disease in Iohexol for measuring GFR | 703</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sederholm Lawesson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Alfredsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Szummer</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">STEMI from a gender perspective: data from the SWEDE-HEART register, a large Swedish prospective cohort</title>
	</analytic>
	<monogr>
		<title level="j">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e008188</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate</title>
		<author>
			<persName><forename type="first">K</forename><surname>Matsushita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Mahmoodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">307</biblScope>
			<biblScope unit="page" from="1941" to="1951" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Cystatin C versus creatinine in determining risk based on kidney function</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Shlipak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Matsushita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Arnlov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="932" to="943" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">An age-calibrated definition of chronic kidney disease: rationale and benefits</title>
		<author>
			<persName><forename type="first">P</forename><surname>Delanaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Glassock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pottel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Biochem Rev</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="17" to="26" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Shlipak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sarnak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="237" to="246" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Measured GFR does not outperform estimated GFR in predicting CKD-related complications</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Propert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1931" to="1937" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Estimated GFR is biased by non-traditional cardiovascular risk factors</title>
		<author>
			<persName><forename type="first">T</forename><surname>Melsom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">M</forename><surname>Fuskevåg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">D</forename><surname>Mathisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Nephrol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="7" to="15" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Estimated GFR associates with cardiovascular risk factors independently of measured GFR</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">D</forename><surname>Mathisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Melsom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">C</forename><surname>Ingebretsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="927" to="937" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Rule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lieske</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="1169" to="1176" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality</title>
		<author>
			<persName><forename type="first">J</forename><surname>Coresh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Turin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Matsushita</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">311</biblScope>
			<biblScope unit="page" from="2518" to="2531" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Costimulation blockade with belatacept in renal transplantation</title>
		<author>
			<persName><forename type="first">F</forename><surname>Vincenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Larsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Durrbach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="770" to="781" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebocontrolled, multicentre trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Caroli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Perico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Perna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="page" from="1485" to="1495" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Tolvaptan in patients with autosomal dominant polycystic kidney disease</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Devuyst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="2407" to="2418" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">A systematic comparison of cockcroft-gault and modification of diet in renal disease equations for classification of kidney dysfunction and dosage adjustment</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mi</forename><forename type="middle">Z</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Pharmacother</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1174" to="1187" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title level="m" type="main">Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function</title>
		<ptr target="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162133.pdf.2014" />
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
